“We aim to recruit 50 patients by summer next year with the expectation that we can be phase three ready in that study by the end of next year.”
→ Read the source episode
StepPharma recruits 50 patients in ET phase 2 trial by 2027-06-30 and achieves phase three readiness by 2027-12-31
Andy Parker predicts StepPharma will move lymphoma trial into safety expansion cohort and make phase two decisions by end of 2026.
Andy Parker predicts StepPharma will complete ET phase two by end of 2027 and begin planning phase three.
Andy Parker predicts StepPharma will raise additional funding within next six months (by January 2027).
Andy Parker predicts phase one readout from solid tumor safety expansion cohorts within 12-15 months (by October 2027).
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.